Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to document the pharmacokinetic parameters of both
levetiracetam and its metabolite, ucb L057, after a single dose of 20 mg/kg of levetiracetam
in epileptic pediatric subjects, aged 1 month to less than 4 years.